AwesomeCapital
Search This Blog
Thursday, September 10, 2026
AbbVie’s atogepant meets Phase 3 LUNA trial goal, significantly reducing menstrual migraine days
AbbVie’s atogepant meets Phase 3 LUNA trial goal, significantly reducing menstrual migraine days versus placebo
AbbVie
plans to submit
atogepant LUNA Phase 3 menstrual migraine data
to health authorities worldwide.
https://finviz.com/stock?t=ABBV&p=d
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.
Newer Post
Older Post
Home
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.